04 July 2022
The Ministry of Industry and Trade of Russia has updated the draft government decree on the introduction of the “second one out” rule in public drugs procurement, PhV reports.
The updated rule, which will be in force from September 2024, will apply to the entire list of strategically important medicines, as Deputy Head of the Ministry of Industry and Trade Vasily Osmakov announced. If the list of strategically important medicines is updated, then the rule will come into force for newly included drugs two years after the amendment.
The publication reports that the project is currently undergoing a conciliation procedure.
The “second one out” mechanism gives an absolute advantage in public bidding procedure to manufacturers that effect full-cycle production of their drugs in the Russian Federation, including the substance synthesis stage. The customer has to reject all other applications if at least one application with such a domestically produced drug is submitted during public procurement.
PrintGrand finale from a veritable stalwart of neuroscience
09 November 2023
Battle of pharma advocates – in search of the ideal migraine therapy
09 November 2023
31 October 2023
01 December 2023
An Indian investor will invest more than 1 billion rubles in a pharmaceutical plant in Nevinnomyssk
01 December 2023
Long COVID study expanded across Europe
30 November 2023
Ethical, Regulatory, and Operational Considerations for Cell and Gene Therapy Research in Children
30 November 2023